Imidazole binding to three apolar distal heme pocket mutants of yeast cytochrome c peroxidase (CcP) has been investigated between pH 4 and 8. The three CcP variants have Arg-48, Trp-51, and His-52 mutated to either all alanine, CcP(triAla), all valine, CcP(triVal), or all leucine residues, CcP(triLeu). The imidazole binding curves for all three mutants are biphasic indicating that each of the mutants exists in at least two conformational states with different affinities for imidazole. At pH 7, the high-affinity conformations of the three CcP mutants bind imidazole between 3.8 and 4.7 orders of magnitude stronger than that of wild-type CcP while the low-affinity conformations have binding affinities about 2.5 orders of magnitude larger than wild-type CcP. Imidazole binding to the three CcP mutants is pH dependent with the strongest binding observed at high pH. Apparent pK a values for the transition in binding vary between 5.6 and 7.5 for the high-affinity conformations and between 6.2 and 6.8 for the low-affinity conformations of the CcP triple mutants. The kinetics of imidazole binding are also biphasic. The fast phase of imidazole binding to CcP(triAla) and CcP(triLeu) is linearly dependent on the imidazole concentration while the slow phase is independent of imidazole concentration. Both phases of imidazole binding to CcP(triVal) have a hyperbolic dependence on the imidazole concentration. The apparent association rate constants vary between 30 and 170 M −1 s −1 while the apparent dissociation rate constants vary between 0.05 and 0.43 s −1
Introduction
Heme enzymes are ubiquitous in nature and catalyze a wide variety of oxidation reactions utilizing either molecular oxygen or hydrogen peroxide as oxidant and some heme enzymes have been used in the synthetic laboratory to catalyze specific oxidations [1, 2] . With advances in recombinant DNA technology and the ability to modify protein structure through site-directed mutagenesis, significant effort has gone into the development of enzymes for use as catalysts in organic synthesis [3, 4] . The utilization of hydrogen peroxide for oxygenation of organic substrates, the so-called "peroxygenase" activity, is a reaction of interest to synthetic chemists since it mimics the monoxygenase reactions of the cytochrome P450s without the need for the additional reductase and cofactor (NADH or NADPH) of the P450 system. Yeast cytochrome c peroxidase (CcP) appears to be a good candidate to serve as a scaffold for developing specific peroxygenases for synthetic purposes. CcP has a low native peroxygenase activity, oxidizing styrene to styrene oxide with steady-state turnover rates of about 10 −4 s −1 at pH 7 [5] and it is very stable to oxidative degradation by hydrogen peroxide [6] . Two factors for the low peroxygenase activity of CcP may be due to the low affinity for small organic substrates within the distal heme pocket and lack of accessibility of the substrate to the heme iron for direct oxygen atom transfer during the catalysis. To test these hypotheses, three CcP mutants were constructed to make the distal heme pocket more apolar [7] . The mutants were constructed by simultaneously replacing Arg-48, Trp-51, and His-52 by either all alanines, CcP(triAla), all valines, CcP(triVal), or all leucines, CcP(triLeu). (See Fig. 1 of the preceding paper [8] for the active site structure of CcP). All three mutants show a 30-to 34-fold increase in the rate of 1-methoxynaphthalene hydroxylation by hydrogen peroxide [9] . The hydroxylation activity by the CcP mutants is only a factor of two slower than naphthalene hydroxylation by rat liver microsomal cytochrome P450. The three apolar CcP mutants have been characterized by UV-vis spectroscopy, catalytic activity, reaction with hydrogen peroxide, and by cyanide binding [7] . The UV-vis spectrum of all three mutants are pH dependent indicating a change in heme ligation over the pH range 4 to 8. The three mutants retain less than 0.02% of wild-type activity, primarily due to the decrease in the rate of reaction with hydrogen peroxide. Binding of cyanide to the three apolar mutants is biphasic indicating that there are at least two slowly-exchanging conformations in each mutant, and that the different conformational states have different cyanide affinities. The binding affinity for cyanide is reduced by at least two orders of magnitude compared to wild-type CcP and the rate of cyanide binding is decreased by at least four orders of magnitude. In this manuscript we report on the further characterization of CcP(triAla), CcP(triVal), and CcP(triLeu) by an investigation of imidazole binding. In contrast to the loss of cyanide affinity, the three apolar mutants show a substantial increase in imidazole affinity compared to wildtype CcP.
In the preceding paper, we have shown that wild-type yeast cytochrome c peroxidase (yCcP) and a recombinant form of CcP (rCcP) have very weak affinities for imidazole with equilibrium dissociation constants (K D ) of about 4 M at pH 7 [8] . These are the weakest imidazole binding affinities reported for any heme protein. Typically, heme protein-imidazole complexes have K D values in the millimolar to micromolar region [10] [11] [12] [13] [14] . Binding of imidazole to the three mutants is biphasic, just as the binding of cyanide. The high-affinity phase is designated by the equilibrium dissociation constant, K D1 , and the low-affinity phase designated by K D2 . The triple mutants have significantly greater affinity for imidazole with both K D1 and K D2 substantially smaller than K D for the CcP/imidazole complex. At pH 7, the values of K D1 for the triple mutants range from 83 μM for CcP(triVal) to 0.60 mM for CcP(triLeu), showing increased imidazole binding affinity of 3.8 to 4.7 orders of magnitude. Even the low-affinity binding phases of the triple mutants bind imidazole more strongly than wild-type CcP with K D2 values ranging from 12 to 17 mM at pH 7, some 2.5 orders of magnitude smaller than K D for the CcP/imidazole complex [8] .
The pH dependence of imidazole binding to the CcP triple mutants has also been investigated, with the values of K D1 and K D2 determined between pH 4 and 8 and the kinetics of binding investigated over the same pH region. Finally, the binding of 1-methylimidazole and 4-nitroimidazole to each of the triple mutants has been determined at pH 7.
Materials and methods

Cloning, expression, and purification of CcP mutants
The expression system for the recombinant CcP (rCcP) used in this study as well as the protocols for construction, expression and purification of the CcP mutants have been previously described [7, 8] .
Other materials
Potassium acetate and potassium phosphate salts were obtained from Fisher Scientific. Imidazole, 1-methylimidazole and 4-nitroimidazole were obtained from Aldrich Chemical Co. Buffers, pH 4.0 to 5.5, were 0.010 M acetate with sufficient KH 2 PO 4 to adjust the ionic strength to 0.100 M. Between pH 5.5 and 8.0, the buffers were mixtures of KH 2 PO 4 and K 2 HPO 4 with an ionic strength 0f 0.100 M.
Spectroscopic measurements and protein concentration determination
Protein spectra were determined as described previously [9] . Concentration of stock protein solutions were determined spectrophotometrically at pH 6.0 using the following extinction coefficients in the Soret band: yCcP, 98 mM [7, 8] .
Equilibrium binding and kinetic measurements
Equilibrium binding studies were performed with the CcP triple mutants as described in the preceding paper for wild-type CcP and CcP(H52L) [8] . Kinetic studies were carried out using an Applied Photophysics Model DX.17 V stopped-flow spectrophotometer. Protein concentrations were typically 1 to 2 μM and the ligand concentrations varied with the reaction but were always 10-fold or greater than the protein concentration. Data were acquired as a minimum of five different ligand concentrations that varied by at least a factor of 5. The data were fit to either a single or double exponential equation using the instrument's software as appropriate. Reported rate constants are the average values from at least 10 absorbance vs. time scans.
Results
Equilibrium binding of imidazole to CcP(triAla)
Imidazole binding to CcP(triAla) is much stronger than binding to wild-type CcP, with essentially complete formation of the imidazole complex at 0.10 M imidazole. Fig. 1 shows the titration of CcP(triAla) at pH 7.0. The Soret maximum shifts from 410 to 413 nm with increasing imidazole concentrations and is accompanied by a substantial increase in the absorbance at 413 nm. Fig. 2 shows plots of the absorbance change at 414 nm as a function of imidazole concentration for the titration of CcP(triAla) at pH 5.5 and 7.0. Both plots are biphasic, with the biphasic character of the titration more noticeable at pH 5.5. Observation of a biphasic equilibrium titration curve suggests two conformations of CcP(triAla) with different imidazole affinities and which do not interconvert on the time scale of the equilibrium experiments. The change in absorbance at 414 nm was fit to Eq. (1), using nonlinear least- squares regression, where K D1 and K D2 represent the equilibrium dissociation constants for the high-and low-affinity phases, respectively. At pH 7.0, the best-fit values for K D1 and K D2 for the CcP(triAla)/imidazole complexes are 0.22 ± 0.05 mM and 12 ± 1 mM, respectively. Values of K D1 and K D2 at pH 7.0 are collected in Table 1 .
Values for K D1 and K D2 were determined at each half pH unit between pH 4.0 and 8.0, Fig. 3 . K D1 and K D2 values as a function of pH are tabulated in Table S1 of Appendix A, Supplementary Material provided with this article. Between pH 4 and 8, the low-affinity phase is the major phase of imidazole binding, accounting for 75 ± 8% of the absorbance change at 414.
Both K D1 and K D2 are pH dependent with the binding strongest at alkaline pH. The pH dependence of K D1 and K D2 can be accounted for by the ionization of a single group, Eq. (2).
In Eq. (2) Table 2 .
The spectrum for 100% formation of the CcP(triAla)/imidazole complex can be calculated from the data shown in Figs. 1 and 2 . The spectrum of the CcP(triAla)/imidazole complex is shown in Fig. S1 of the supplementary data and selected spectral parameters are collected in Table 3 . The CcP(triAla)/imidazole complex has a Soret maximum at 413 nm with an extinction coefficient of 143 mM −1 cm −1 and α (shoulder) and β bands at 564 and 536 nm, respectively.
Kinetics of imidazole binding to CcP(triAla)
Binding of imidazole to CcP(triAla) was followed by stopped-flow spectrophotometry at 414 nm using pseudo-first-order conditions with imidazole in excess. Binding of imidazole to CcP(triAla) is biphasic, with the observed rate constants for the fast and slow phases of the reaction designated k fast and k slow , respectively. The rate constant for the fast phase of the reaction is linearly dependent upon the imidazole (2) of the text using non-linear least squares regression. K D1 increases from 0.13 mM at high pH to N25 mM at low pH with an apparent pK a of 5.6 ± 0.5. K D2 increases from 6.4 mM at high pH to 570 mM at low pH with an apparent pK a of 6.8 ± 0.1. Best-fit parameters are collected in 
The apparent association and dissociation rate constants can be determined from the slope and intercept of plots such as that shown in Fig. S2 . Observed rate constants that are independent of ligand concentration such as k slow are typically associated with conformational changes within the protein or protein-ligand complex that limit the rate. We define the rate-limiting unimolecular rate constant k max . , respectively. The pH dependence of k a app can be attributed to the ionization of a single group but we will see later that k a app for the fast phase of the CcP(triLeu)/imidazole reaction is influenced by two ionizable groups. We choose to fit the CcP(triAla) data to an equation representing two ionizable groups with the proviso that ionization of the second group does not influence the CcP(triAla) data between pH 4 and 8. 
are the low-, intermediate, and high-pH values of k a app , while K a1 and K a2 are the acid dissociation constants for the ionizable groups that influence the reaction. For the CcP(triAla) data, either k a neut equals k a base or pK a2 is greater than 9 such that it does not influence the data at pH 8. Nonlinear least squares regression was used to determine the best-fit values for k a acid , k a neut , and the pK a1 value for the more acidic ionizable group. The best-fit parameters are collected in Table 5 .
The 6.4 ± 0.7 6.7 ± 2.3 9.4 ± 3.1 pK a2
6.8 ± 0.1 6.2 ± 0.3 6.8 ± 0.4 a Parameters are defined in Eq. (2) of the text. the slow kinetic phase of the reaction is attributed to the binding of imidazole to the high-affinity conformation of CcP(triAla) and this binding is limited by an isomerization within the high-affinity conformation characterized by k slow = k max .
Equilibrium binding of imidazole to CcP(triLeu)
The binding of imidazole to CcP(triLeu) is, in general, similar to the binding of imidazole to CcP(triAla). Fig. 5 shows a spectroscopic titration of CcP(triLeu) with imidazole at pH 7.0. The Soret maximum shifts from 405 to 412 nm during the titration with a substantial increase in absorptivity. A plot of the change in absorbance as a function of imidazole concentration, Fig. S4 supplementary data, is biphasic. Fitting the absorbance changes to Eq. (1) gives best-fit values of 0.60 ± 0.04 mM and 17 ± 7 mM for K D1 and K D2 , respectively, Table 1 . The values for K D1 and K D2 are slightly larger than those for CcP(triAla) indicating somewhat weaker binding of imidazole by CcP(triLeu). However, the high-affinity imidazole binding phase of CcP(triLeu) is the dominant phase, accounting for 78% of absorbance change at pH 7.
In contrast to imidazole binding to CcP(triAla), binding of imidazole to CcP(triLeu) is monophasic between pH 4.0 and 6.5 and biphasic between pH 7.0 and 8.0, Fig. 6 . At lower pH, the experimental equilibrium constant is consistent with binding to the high-affinity conformation of CcP(triLeu). Binding to the low-affinity conformation of CcP(triLeu) can only be detected between pH 7 and 8, where it accounts for an average of 30 ± 7% of the absorbance change at 414 nm. Values of K D1 and K D2 are tabulated in Table S3 of the supplementary data.
The pH dependence of K D1 can be attributed to the effects of a single ionizable group just as for the CcP(triAla)/imidazole reaction. Fitting K D1 to Eq. (2) gives best-fit values of 120 ± 60 mM and 0.22 ± 0.15 mM, for K D1 acid and K D1 base , respectively, Table 2 . The ionizable group has a pK a of 7.5 ± 0.4. , respectively. The association rate constant, k a app , increases as a function of pH and was fit to Eq. (4) of the text where only the group with pK a1 affects the rate constant. k a app increases from a value of 2.2 ± 0.4 M −1 s −1 at low pH to 99 ± 25 M −1 s −1 at high pH with an apparent pK a1 of 7.0 ± 0.2. Best-fit parameters are collected in Table 5 . Experimental conditions: 0.10 M ionic strength buffers, 25°C. The spectrum for 100% formation of the CcP(triLeu)/imidazole complex can be calculated from the data shown in Figs. 5 and S4. The spectrum of the CcP(triLeu)/imidazole complex is shown in Fig. S1 of the supplementary data and selected spectral parameters are collected in Table 3 . The CcP(triLeu)/imidazole complex has a Soret maximum at 412 nm with an extinction coefficient of 124 mM −1 cm −1 and α (shoulder) and β bands at 564 and 532 nm, respectively.
Kinetics of imidazole binding to CcP(triLeu)
The kinetics of imidazole binding to CcP(triLeu) is biphasic over the pH range 4.0 to 8.0 even though the equilibrium titrations are monophasic between pH 4.0 and 6.5 (Fig. 6) . The rate constant for the fast phase of the reaction is linearly dependent upon the imidazole concentration, Fig. S5 Table S4 supplementary data, and plotted in Fig. 7 .
Although the pH dependencies of the CcP(triLeu) and CcP(triAla) reactions are similar (Figs. 4 and 7) there are some differences. While k a app for the CcP(triAla)/imidazole reaction appears to be influenced by a single ionizable group, k a app for the CcP(triLeu)/imidazole reaction has a maximum value near pH 7 indicating that at least two ionizable groups affect the reaction. The pH dependence of k a app for the CcP(triLeu)/imidazole reaction can be described by Eq. (4) where both ionizable groups influence the data. The best-fit values for the parameters defined by Eq. (4) are collected in Table 5 . In order to get a reasonable fit we had to set pK a1 ≤ pK a2 and under these conditions, the values of pK a1 and pK a2 converge to the same value of 7.3. The system is not well defined, primarily because we cannot determine the high pH limit of the association rate constant, and the estimated error in the parameters is large. Interestingly, and providing some support for the accuracy of the fitting procedure, is that the values for k a acid and k a neut are identical to those for the CcP(triAla) reaction, Table 5 . The value of k d app is independent of pH with an average value of 0.38 ± 0.12 s − 1 . However, k slow = k max has a small pH dependence and we fit the pH dependence to an equation analogous to that of Eq. (4) with the proviso that the second ionization does not influence the reaction. Best-fit values for k acid and k neut and the pK a1 value that influences k max are collected in Table 5 . If we just average k max over the pH range 4 to 8 the average value is 0.048 ± 0.018 s where equilibrium values of K D2 could not be extracted from the titration curves. Fitting a composite data set consisting of the K D2 equilibrium data and the K D kin data to Eq. (2) gives best-fit values of 160 ± 60 mM and 9.4 ± 3.1 mM, for K D2 acid and K D2 base , respectively. The ionizable group has a pK a of 6.8 ± 0.4, Table 2 .
Equilibrium binding of imidazole to CcP(triVal)
Equilibrium binding of imidazole to CcP(triVal) is similar to the binding of imidazole to CcP(triAla). Fig. 8 shows a spectroscopic titration of CcP(triVal) with imidazole at pH 7.0. The Soret maximum shifts from 406 to 412 nm during the titration with a substantial increase in absorptivity. A plot of the change in absorbance as a function of imidazole concentration, Fig. S6 supplementary data, is biphasic. Fitting the absorbance changes to Eq. (1) gives best-fit values of 83 ± 5 μM and 12 ± 4 mM for K D1 and K D2 , respectively, Table 1 . The high affinity phase of the binding accounts for 68% of the absorbance change in the Soret region at pH 7. In addition, the high-affinity phase for imidazole binding to CcP(triVal) is the strongest imidazole binding for any CcP mutant we have investigated, 4.7 orders of magnitude stronger than for wildtype CcP and less than 50-times weaker than the strongest reported binding of imidazole binding to any heme protein [15] .
The pH dependence of K D1 and K D2 for the CcP(triVal)/imidazole reaction is shown in Fig. 9 and values are tabulated in Table S5 of the supplementary data. The pH dependence of both K D1 and K D2 can be attributed to the effects of a single ionizable group and fit to Eq. (2). Best-fit values for the parameters defined in Eq. (2) are collected in Table 2 . The high-affinity phase of binding gives best-fit values of 9.6 ± 5.5 mM and 96 ± 7 μM, for K D1 acid and K D1 base , respectively, and a The data were fit to Eq. (2) of the text using non-linear least squares regression. K D1 increases from 0.22 mM at high pH to 120 mM at low pH with an apparent pK a of 7.5. The combination of K D2 and K D kin increases from 9.4 mM at high pH to 160 mM at low pH with an apparent pK a of 6.8. Best-fit parameters are collected in Table 2 . . Best-fit parameters are collected in Table 5 . Experimental conditions: 0.10 M ionic strength buffers, 25°C.
pK a of 5.7 ± 0.1 for the ionizable group, Table 2 . The low-affinity phase of binding gives best fit values of 0.38 ± 0.39 M and 6.7 ± 2.3 mM, for K D1 acid and K D1 base , respectively, and a pK a of 6.2 ± 0.3 for the ionizable group, Table 2 . The high affinity phase accounts for an average of 67 ± 10% of the absorbance change over the pH range 4 to 8.
The spectrum for 100% formation of the CcP(triVal)/imidazole complex can be calculated from the data shown in Figs. 8 and S6 . The spectrum of the CcP(triVal)/imidazole complex is shown in Fig. S1 of the supplementary data and selected spectral parameters are collected in Table 3 .
Kinetics of imidazole binding to CcP(triVal)
The binding of imidazole to CcP(triVal) is biphasic but in contrast with the CcP(triAla) and CcP(triLeu) reactions, both k fast and k slow are dependent upon the imidazole concentration, increasing linearly at low concentrations but reaching a limiting value at high ligand concentrations, Fig. S7 , supplementary data. In this case three parameters are required to fit the imidazole concentration dependence of both k fast and k slow . To compare the CcP(triVal) imidazole kinetic parameters with those for CcP(triAla) and CcP(triLeu), we use k a app , k d app , and a maximum rate constant, k max , which is the limiting rate at infinite imidazole concentration, to define an empirical equation shown in Eq. (5). The actual interpretation of the parameters will . The apparent pK a for the transition between low and high pH rates is 6.1 ± 0.5.
The maximum rates observed for both phases of the CcP(triVal)/imidazole reaction, k max , are similar to k slow = k max for the CcP(triAla) reaction in that all three are pH and concentration independent. The magnitudes vary by about a factor of 50 and this may be the reason for the different concentration dependencies for the rates of imidazole binding to the triple mutants. The values of k max for the fast and slow phases of the CcP(triVal) reaction and slow phase of the CcP(triAla) reactions are 1.5 ± 0.3, 0.17 ± 0.04, and 0.032 ± 0.011 s −1 , respectively. k slow = k max for the CcP(triLeu)/imidazole reaction in concentration independent but does have a small pH dependence; it varies from 0.032 ± 0.003 s − 1 at low pH to 0.077 ± 0.011 s − 1 at high pH. The apparent pK a for the transition between low-and high-pH rates is 6.7 ± 0.4.
3.7.
Binding of 1-methylmidazole binding to CcP(triAla), CcP(triLeu), and CcP(triVal) at pH 7
Just as with imidazole, 1-methylimidazole (MIM) binds to CcP(triAla), CcP(triVal), and CcP(triLeu) more strongly than it binds to yCcP. Fig. 11 shows the CcP(triLeu)/MIM titration while Figs S8 and S9 show the CcP(triAla)/MIM and CcP(triVal)/MIM titrations at pH 7.0. The binding of MIM to CcP(triLeu) is monophasic, Fig. S10 , with a K D value of 39 ± 3 mM. This is about twice as large as K D2 for imidazole binding to CcP(triLeu), Table 1 , and we associate MIM binding to the low affinity conformation of CcP(triLeu). The titrations of CcP(triAla) and CcP(triVal) are biphasic, Figs. S11 and S12. For CcP(triAla), the low affinity phase, 2) of the text using non-linear least squares regression. K D1 increases from 0.096 mM at high pH to 9.6 mM at low pH with an apparent pK a of 5.7 ± 0.1. K D2 increases from 6.8 mM at high pH to 380 mM at low pH with an apparent pK a of 6.2 ± 0.3. Best-fit parameters are collected in Table 2 .
with a K D2 of 0.11 ± 0.01 M, is the dominant phase, accounting for about 70% of the absorbance change in the Soret region. K D1 for the CcP(triAla)/ MIM reaction is 0.35 ± 0.34 mM. The high-affinity phase is the dominant phase in the CcP(triVal)/MIM titration accounting for 77% of the absorbance change in the Soret region. K D1 and K D2 values are 0.16 ± 0.04 mM and 6.8 ± 3.3 mM, respectively, Table 1 . The spectra for 100% complex formation for the MIM complexes of CcP(triAla), CcP(triVal), and CcP(triLeu) can be calculated from the titration data and selected spectral parameters are collected in Table 3. 3.8. Binding of 4-nitroimidazole to CcP(triAla), CcP(triLeu), and CcP(triVal) at pH 7.0
The spectroscopic titration of CcP(triVal) by 4-nitroimidazole is shown in Fig. 12 while the CcP(triAla)/4NI and CcP(triLeu)/4NI titrations are shown in Figs. S13 and S14 of the supplemental data. Addition of saturated solution of 4NI to CcP(triVal) causes a 5 nm red-shift of the Soret band with a 34% increase in absorbance, consistent with formation of a six-coordinate low-spin heme complex. Over the limited 4NI concentration range available (up to about 5 mM), 4NI binds to CcP(triVal) in a monophasic manner, Fig. S15 , with a K D value of 0.56 ± 0.02 mM, Table 1 . The spectrum for complete formation of the CcP(triVal)/4NI complex can be calculated from the data in Figs. 12 and S15. Selected spectroscopic parameters are collected in Table 3 .
Spectroscopic changes associated with adding saturated 4NI to CcP(triAla), Fig. S13 , and CcP(triLeu), Fig. S14 , are much smaller than the changes observed by adding 4NI to CcP(triVal). This may be because high-affinity binding of 4NI is not evident for CcP(triAla) and CcP(triLeu) while binding of 4NI to CcP(triVal) is primarily to the high-affinity conformation. Assuming that the spectrum of the 4NI complex is similar for the high-and low-affinity conformations of the CcP triple mutants and using the spectra of the CcP(triVal)/4NI and metMb/4NI complexes as references, we can estimate K D2 values for binding of 4NI to CcP(triAla) and CcP(triLeu) of 16 ± 11 and 35 ± 13 mM, respectively, Table 1.
Discussion
Spectroscopic properties of the imidazole-CcP complexes at pH 7
The electronic absorption spectra of twelve imidazole/CcP complexes were determined at pH 7, Table 3 . These include the imidazole derivatives of yCcP, rCcP, CcP(triAla), CcP(triVal), CcP(TriLeu), the 1-methylimidazole derivatives of yCcP, rCcP, CcP(H52L), CcP(triAla), CcP(triVal), CcP(TriLeu), and the 4-nitroimidazole derivative of CcP(triVal). We were unable to obtain the spectra of the imidazole/ CcP(H52L) complex and the 4-nitroimidazole complexes of yCcP, CcP(H52L), CcP(triAla) and CcP(triLeu) due to the weak affinity for these protein ligand combinations. In some cases the UV regions of the spectra were not determined due to the high absorbance of the ligands at the concentrations necessary to saturate the proteins. The dissociation rate constant for the fast phase of imidazole binding is independent of pH, with an average value of 0.25 ± 0.08 s A major consideration in interpreting the spectrum of imidazole complexes is to determine if the bound imidazole is present in its neutral form or as the imidazolate anion. Binding of imidazole to the heme iron can significantly increase the acidity of the bound ligand promoting imidazolate formation. Model studies have shown that the electronic absorption spectrum of imidazole/heme complexes can distinguish between imidazole and imidazolate binding. The Soret bands of imidazolate/heme complexes are red-shifted with a less intense Soret band compared to the Soret bands of imidazole/heme complexes [8, [15] [16] [17] [18] .
4.1.1. Spectroscopic properties of the 1-methylimidazole complexes of CcP and the CcP mutants at pH 7 1-Methylimidazole binding to yCcP and the four distal pocket CcP mutants is sufficiently strong that spectra for 100% complex formation can be determined for all six proteins at pH 7, Table 3 . MIM cannot ionize to form imidazolate so the observed spectra are due to binding of neutral imidazole to the heme. The Soret bands for the seven MIM complexes listed in Table 3 Table 3 .
In addition to the changes in the Soret band, the visible region of the spectra show the characteristic changes associated with formation of six-coordinate, low-spin complexes of the heme iron. The heme group in yCcP is predominantly five-coordinate, high-spin with prominent charge-transfer bands near 508 and 645 nm. Upon binding of MIM, the charge-transfer bands diminish in intensity and are replace by prominent α and β bands, with the β band dominating the visible region of the spectrum. The β band positions for the yCcP/MIM and the CcP(H52L)/MIM complexes are at 542 and 544 nm, respectively, while the β band positions for the three triple mutant/MIM complexes are between 534 and 536 nm, similar to the β band of the metMb/MIM complex.
Spectroscopic properties of the imidazole complexes of CcP and the CcP mutants at pH 7
Binding of imidazole to the heme iron significantly increase the acidity of the ligand and we need to consider the possibility that bound imidazole can ionize to the imidazolate anion. Binding of imidazole to yCcP is unusual in that there is a decrease in the maximum extinction coefficient form 98 to 85 mM
, accompanied by a shift in the Soret maximum form 408 to 412 nm [8] . More importantly, the largest increase in the difference spectrum between the imidazole complex and wild-type yCcP occurs at 436 nm. As discussed in the preceding paper [8] , the increase in absorbance near 436 nm is a signature for imidazolate binding and we concluded that the ligand in the yCcP/ imidazole complex is between 22 and 32% ionized at pH 7.
The binding of imidazole to wild-type CcP and the four CcP mutants cause a 4 to7 nm red-shift in the position of the Soret band but the absorptivity changes of the imidazole complexes fall into two groups. The spectra of the yCcP and CcP(H52L) imidazole complexes show the largest increases in absorptivity at 436 and 442 nm, respectively [8] , while the imidazole complexes of rCcP [8] and the triple mutants, Figs. 1, 5, and 8, show the largest increases in absorptivity between 415 and 420 nm. The spectra of the imidazole complexes of the CcP triple mutant look very much like the CcP/MIM complexes, Figs. 11, S8, and S9, and we conclude that the neutral form of imidazole is bound to the triple mutants at pH 7. The apolar nature of the distal heme pocket in the CcP triple mutants inhibit ionization of the bound imidazole and the net positive charge on the Fe(III) heme is largely compensated by the negativelycharged Asp-235 in the proximal heme pocket.
Spectroscopic properties of the 4-nitroimidazole complexes of the CcP triple mutants at pH 7
Binding of 4-nitroimidazole to yCcP, CcP(H52L), CcP(triAla), and CcP(triLeu) is too weak to determine the spectrum of the 4NI complexes for these proteins. The CcP(triVal) binds 4NI three orders of magnitude more strongly than yCcP and the spectrum of the CcP(triVal)/4NI complexes could be determined. The Soret band for the CcP(triVal)/4NI complex occurs at 416 nm with an extinction coefficients are 110 mM Table 3 , similar to the spectroscopic parameters for the metMb/4NI complex, Table 3 [19] . There is no evidence for bound imidazolate in any of the three triple mutants, with the largest increase in the difference spectra occurring between 418 and 420 nm, Figs. 12, S13, and S14. In spite of the very acidic nature of 4NI, with a pK a of 9.5 for the imidazole/ imidazolate ionization in the free ligand, the apolar nature of the distal heme pocket in the CcP triple mutants destabilizes formation of a negatively-charged bound ligand compared to the neutral ligand.
Mechanism of imidazole binding to the CcP triple mutants
The major finding of this work is that making the distal heme pocket in CcP more apolar significantly enhances CcP's affinity for imidazole, MIM and 4NI. Although the binding of imidazole to all three triple mutants is biphasic, even the low-affinity binding phase has imidazole affinities that are 240-to 330-fold greater than wild-type CcP, Table 1 . The high-affinity forms of the triple mutants bind imidazole with 6700-to 48,000-fold greater affinity than CcP, an almost 5-order of magnitude increase in imidazole affinity for CcP(triVal). The properties of the CcP triple mutants are complex [7, 8] and a more detailed consideration of imidazole binding can provide further characterization of these mutants. In addition to the biphasic equilibrium binding curves, the binding kinetics are biphasic as well. CcP(triAla) and CcP(triLeu) have a fast kinetic phase that is linearly dependent upon the imidazole concentration and a slow kinetic phase that is independent of ligand concentration. On the other hand, both phases of imidazole binding to CcP(triVal) are hyperbolic functions of the imidazole concentration, Fig. S7 . A previous study of cyanide binding to the three CcP triple mutants show exactly the same equilibrium and kinetic behavior [7] , indicating that these properties are not unique to imidazole binding but properties of the mutants.
The biphasic nature of the equilibrium titration curves indicate that each of the CcP triple mutants exist in at least two conformations with different ligand affinity. The conformations do not interconvert on the time scale of the equilibrium experiments and each conformation can be treated as independent species in solution. The saturation kinetics for both phases of ligand binding to CcP(triVal) indicate that an unimolecular step limits the rate of product formation. The two most common mechanisms for this type of kinetic behavior are either formation of a precursor complex, followed by a unimolecular conversion to the final product or the presence of a closed form of the enzyme in which the rate of opening limits the binding rate. At the moment, we cannot distinguish between these two mechanisms. We will use the precursor complex mechanism to discuss the equilibrium and kinetic properties of imidazole binding to the CcP triple mutants in this section. A consideration of the closed conformation mechanism is given in the supplementary data. The precursor complex mechanism is shown in Eq. (6) . To be consistent with the experimental observations, formation of the precursor complex cannot be associated
with significant spectroscopic changes, meaning that the ligand is not bound to the heme in EL ⁎ , rather heme binding occurs in the EL ⁎ /EL isomerization step. In order to convert all of the enzyme to the heme-bound imidazole complex, as suggested by the large extinction coefficients in the Soret region for the final complexes, Table 3 , k 3 must be significantly larger than k 4 . Assuming that the EL ⁎ is in a steady-state during the reaction, the observed rate constant is described by Eq. (5) above. The apparent kinetic parameters are expressed in terms of the rate constants defined in the mechanism in Eqs. (7) to (9) . For CcP(triVal), all three kinetic parameters
can be determined for both imidazole binding phases, Table 4 . The slow kinetic phases for CcP(triAla) and CcP(triLeu) are independent of ligand concentration, consistent with Eq. (5) if the first terms in both the numerator and denominator are very large compared to the second terms. In this case, k slow equals k max for the high-affinity imidazole binding phase of the reaction, Table 4 . At pH 7, binding of imidazole to the low-affinity conformation of the CcP triple mutants is similar to that of imidazole binding to metmyoglobin [10] [11] [12] [13] For the precursor complex mechanism to be consistent with observation, k 3 must be much larger than both k 2 and k 4 and under these circumstances Eq. (7) predicts that k a app will be equal to k 1 , the true association rate constant for formation of the precursor complex. Under conditions where k fast is linearly dependent on imidazole concentration, this will also be the rate of formation of the final complex so the comparison of k a app for the triple mutants with k a for the metmyoglobin reactions is . The lower values of k d app for the triple mutants compared to metmyoglobin can be at least partly attributable to the observation that k d app provides a lower limit for the true ligand dissociation rate from the precursor complex, k 2 , since the k 4 /(k 2 + k 3 ) term must be much less than 1. The pH dependencies of both the apparent association and dissociation rate constants for metmyoglobin and the low-affinity conformations of the CcP triple mutants are similar, with the association rate constant increasing with increasing pH and the dissociation rate constant independent of pH. The major difference between imidazole binding to the low-affinity conformations of the CcP triple mutants and to metmyoglobin is that conformational transitions limit the maximum rate of imidazole binding to the CcP triple mutants and also the rate of ligand dissociation.
Conclusions
The CcP triple mutants, with their apolar distal heme pockets, have very interesting properties. Their spectroscopic properties are pH dependent, with the low pH forms having predominantly fivecoordinate, high-spin hemes and the high-pH forms having predominantly six-coordinate, low-spin hemes [8] . Ligand binding studies indicate that all three triple mutants have at least two independent conformational forms that have differential ligand affinity. Binding of imidazole, 1-methylimidazole, and 4-nitroimidazole to the low-affinity conformations is about two-to three-orders of magnitude stronger than binding to wild-type CcP and is similar to the binding of these ligands to metmyoglobin. The high-affinity conformations bind imidazole up to 4.7 orders of magnitude stronger than wild-type CcP. While imidazole binding is enhanced in the triple mutants, cyanide binding is severely inhibited [7] . The high-and low-affinity conformations of the CcP triple mutants bind cyanide three to five orders of magnitude weaker than wild-type CcP at pH 7 [7, 20] . These dramatic differences in ligand binding properties of the CcP triple mutants compared to wild-type CcP are also reflected in the catalytic activity of the enzyme. The reaction between CcP and hydrogen peroxide mimics the binding of HCN, both requiring base catalysis from the distal histidine to bind to the heme iron. Due to a lack of the distal histidine residue, the CcP triple mutants react very slowly with HCN and with hydrogen peroxide, having bimolecular rate constants that are three to seven orders of magnitude smaller than that of wild-type CcP. The low rate of reaction with hydrogen peroxide leads to substantially decreased peroxidase activity of the triple mutants, less than 0.02% under normal assay conditions [7] . On the other hand, due to increased binding of small, apolar organic substrates within the distal heme pocket of the triple mutants, the non-native peroxygenase activity is increased up to 34-fold [9, 21] .
Abbreviations
CcP generic abbreviation for cytochrome c peroxidase yCcP authentic yeast cytochrome c peroxidase isolated from S. cervisiae rCcP recombinant cytochrome c peroxidase expressed in E. coli with an amino acid sequence identical to that of yCcP CcP(TriAla) a triple point mutation of rCcP with R48A/W51A/H52A CcP(TriVal) a triple point mutaion with R48V/W51V/H52V CcP(TriLeu) a triple point mutation of rCcP with R48L/W51L/H52L MIM 1-methylimidazole 4NI 4-nitroimidazole
